Industry
Aepodia
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
Failure Rate
33.3%
1 terminated/withdrawn out of 3 trials
Success Rate
66.7%
-19.8% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT03594890Phase 1Completed
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
Role: collaborator
NCT02609022Phase 1Completed
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
Role: collaborator
NCT03165435Phase 2Withdrawn
A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis
Role: collaborator
All 3 trials loaded